Robert Cherill
Novartis (United States)(US)
Publications by Year
Research Areas
Dermatology and Skin Diseases, Allergic Rhinitis and Sensitization, Food Allergy and Anaphylaxis Research, Contact Dermatitis and Allergies, Asthma and respiratory diseases
Most-Cited Works
- → The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis(2001)1,169 cited
- → Efficacy and Safety of Pimecrolimus Cream in the Long-Term Management of Atopic Dermatitis in Children(2002)404 cited
- → Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants(2003)200 cited
- → Validation of the Eczema Area and Severity Index for atopic dermatitis in a cohort of 1550 patients from the pimecrolimus cream 1% randomized controlled clinical trials programme(2004)149 cited
- Pimecrolimus cream 1%: a potential new treatment for chronic hand dermatitis.(2004)
- → Oral pimecrolimus in the treatment of moderate to severe chronic plaque-type psoriasis: a double-blind, multicentre, randomized, dose-finding trial(2005)56 cited
- → Efficacy and tolerability of three different doses of oral pimecrolimus in the treatment of moderate to severe atopic dermatitis: a randomized controlled trial(2005)49 cited
- → Sustained Efficacy and Safety of Pimecrolimus Cream 1% when Used Long‐term (up to 26 Weeks) to Treat Children with Atopic Dermatitis(2008)40 cited
- → Pimecrolimus cream 1%: A new development in nonsteroid topical treatment of inflammatory skin diseases(2001)25 cited
- → SDZ ASM 981 cream 1% is effective and safe in children and adolescents with atopic dermatitis(2001)5 cited